Masimo (NASDAQ:MASI) Given New $200.00 Price Target at BTIG Research

Masimo (NASDAQ:MASI) had its price objective hoisted by BTIG Research from $198.00 to $200.00 in a research report report published on Thursday morning, Marketbeat reports. They currently have a buy rating on the medical equipment provider’s stock.

MASI has been the subject of several other reports. Wells Fargo & Company reduced their target price on Masimo from $190.00 to $187.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Wall Street Zen upgraded Masimo from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Piper Sandler raised their target price on shares of Masimo from $200.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 6th. Zacks Research downgraded shares of Masimo from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 24th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Monday. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Masimo presently has a consensus rating of “Hold” and a consensus price target of $188.80.

Masimo Trading Up 3.0%

Shares of NASDAQ:MASI opened at $142.26 on Thursday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.92 and a current ratio of 2.84. The stock has a market capitalization of $7.64 billion, a price-to-earnings ratio of -13.50, a PEG ratio of 1.60 and a beta of 1.26. Masimo has a 1-year low of $133.70 and a 1-year high of $194.88. The company has a 50 day moving average price of $145.85 and a 200 day moving average price of $151.97.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share (EPS) for the quarter. The company had revenue of $617.00 million for the quarter. Masimo had a positive return on equity of 33.04% and a negative net margin of 33.20%. On average, research analysts anticipate that Masimo will post 4.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MASI. Twin Tree Management LP purchased a new stake in Masimo in the 1st quarter worth approximately $29,000. MAI Capital Management increased its stake in shares of Masimo by 176.7% in the second quarter. MAI Capital Management now owns 202 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 129 shares during the last quarter. Hilltop National Bank purchased a new stake in shares of Masimo during the second quarter worth $37,000. Smartleaf Asset Management LLC boosted its position in Masimo by 80.0% during the third quarter. Smartleaf Asset Management LLC now owns 306 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 136 shares during the last quarter. Finally, Advisory Services Network LLC acquired a new stake in Masimo during the third quarter valued at $46,000. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.